Giriraj T Kulkarni

Prof. Dr. Giriraj T Kulkarni

Gokaraju Rangaraju College of Pharmacy, Hyderabad, India
+1
orcid
Faculty of Pharmacy, DIT University, Dehradun

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
NDNeerupma Dhiman
Neerupma Dhiman
RARajendra Awasthi
Rajendra Awasthi
BSBhupesh Sharma
Bhupesh Sharma
HKHarsha Kharkwal
Harsha Kharkwal
GKGiriraj T Kulkarni
Giriraj T Kulkarni
Nanotechnology has made a great impact on the pharmaceutical, biotechnology, food, and cosmetics industries. More than 40% of the approved drugs are lipophilic and have poor solubility. This is the major rate-limiting step that influences the release profile and bioavailability of drugs. Several approaches have been reported to administer lipophilic drugs with improved solubility and bioavailability. Nanotechnology plays a crucial role in the targeted delivery of poorly soluble drugs. Nanotechnology-based drug delivery systems can be classified as solid lipid nanoparticulate drug delivery systems, emulsion-based nanodrug delivery systems, vesicular drug delivery systems, etc. Nanotechnology presents a new frontier in research and development to conquer the limitations coupled with the conventional drug delivery systems through the formation of specific functionalized particles. This review presents a bird's eye view on various aspects of lipid nanoparticles as carriers of bioactive molecules that is, synthesis, characterization, advantage, disadvantage, toxicity, and application in the medical field. Update on recent development in terms of patents and clinical trials of solid lipid nanoparticles (SLNs) and nanostructure lipid carriers (NLCs) have also been discussed in this article.

15 December 2010 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DSDhananjay S. Singare
Dhananjay S. Singare
SMSeshasai Marella
Seshasai Marella
KGK. Gowthamrajan
K. Gowthamrajan
GKGiriraj T Kulkarni
Giriraj T Kulkarni
RVRajesh Vooturi
Rajesh Vooturi
PRParchuri Srinivasa Rao
Parchuri Srinivasa Rao

20 October 2010 in Drug Delivery
Verified
Journal Article
Closed access
PDF file
VPVivek K. Pawar
Vivek K. Pawar
SKShaswat Kansal
Shaswat Kansal
GGGarima Garg
Garima Garg
RARajendra Awasthi
Rajendra Awasthi
DSDeepak Singodia
Deepak Singodia
GKGiriraj T Kulkarni
Giriraj T Kulkarni
In the present era, gastroretentive dosage forms (GRDF) receive great attention because they can improve the performance of controlled release systems. An optimum GRDF system can be defined as a system which retains in the stomach for a sufficient time interval against all the physiological barriers, releases active moiety in a controlled manner, and finally is easily metabolized in the body. Physiological barriers like gastric motility and gastric retention time (GRT) act as obstacles in developing an efficient GRDF. Gastroretention can be achieved by developing different systems like high density systems, floating drug delivery systems (FDDS), mucoadhesive systems, expandable systems, superporous systems, and magnetic systems. All these systems have their own merits and demerits. This review focused on the various aspects useful in development of GRDF including the current trends and advancements.

Verified
Journal Article
Open access
PDF file
PTPriti Tagde
Priti Tagde
Agnieszka Barbara NajdaAgnieszka Barbara Najda
Agnieszka Barbara Najda
KNKalpana Nagpal
Kalpana Nagpal
GKGiriraj T Kulkarni
Giriraj T Kulkarni
Muddaser ShahMuddaser Shah
Muddaser Shah
HRHabibur Rahman
Habibur Rahman
Breast cancer is one of the most common types of cancer among women globally. It is caused by mutations in the estrogen/progesterone receptors and conventional treatment methods are commonly utilized. About 70–80 percent of individuals with the early-stage non-metastatic disease may be cured. Conventional treatment is far less than the optimal ratio, as demonstrated through the high mortality rate of women with this cancer. However, conventional treatment methods like surgery, radiotherapy, and chemotherapy are not as effective as expected and lead to concerns about low bioavailability, low cellular uptake, emerging resistance, and adverse toxicities. A nanomedicine-based approach is a promising alternative for breast cancer treatment. The present era is witnessing rapid advancements in nanomedicine as a platform for investigating novel therapeutic applications and modern intelligent healthcare management strategies. This paper focuses on nanomedicine-based therapeutic interventions that are becoming more widely accepted for improving treatment effectiveness and reducing undesired side effects in breast cancer patients. By evaluating the state-of-the-art tools and taking the challenges involved into consideration, various aspects of the proposed nano-enabled therapeutic approaches have been discussed in this review.

9 July 2021 in Frontiers in Chemistry
Verified
Journal Article
Open access
SCSubhash Chander
Subhash Chander
GKGiriraj T Kulkarni
Giriraj T Kulkarni
NDNeerupma Dhiman
Neerupma Dhiman
HKHarsha Harsha Kharkwal Kharkwal
Harsha Harsha Kharkwal Kharkwal
Hydrogels possess a unique three-dimensional, cross-linked network of polymers capable of absorbing large amounts of water and biological fluids without dissolving. Nanohydrogels (NGs) or nanogels are composed of diverse types of polymers of synthetic or natural origin. Their combination is bound by a chemical covalent bond or is physically cross-linked with non-covalent bonds like electrostatic interactions, hydrophobic interactions, and hydrogen bonding. Its remarkable ability to absorb water or other fluids is mainly attributed to hydrophilic groups like hydroxyl, amide, and sulphate, etc. Natural biomolecules such as protein- or peptide-based nanohydrogels are an important category of hydrogels which possess high biocompatibility and metabolic degradability. The preparation of protein nanohydrogels and the subsequent encapsulation process generally involve use of environment friendly solvents and can be fabricated using different proteins, such as fibroins, albumin, collagen, elastin, gelatin, and lipoprotein, etc. involving emulsion, electrospray, and desolvation methods to name a few. Nanohydrogels are excellent biomaterials with broad applications in the areas of regenerative medicine, tissue engineering, and drug delivery due to certain advantages like biodegradability, biocompatibility, tunable mechanical strength, molecular binding abilities, and customizable responses to certain stimuli like ionic concentration, pH, and temperature. The present review aims to provide an insightful analysis of protein/peptide nanohydrogels including their preparation, biophysiochemical aspects, and applications in diverse disciplines like in drug delivery, immunotherapy, intracellular delivery, nutraceutical delivery, cell adhesion, and wound dressing. Naturally occurring structural proteins that are being explored in protein nanohydrogels, along with their unique properties, are also discussed briefly. Further, the review also covers the advantages, limitations, overview of clinical potential, toxicity aspects, stability issues, and future perspectives of protein nanohydrogels.

31 October 2019 in Central Nervous System Agents in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
ASAnurag Kumar Singh
Anurag Kumar Singh
SSSantosh Kumar Singh
Santosh Kumar Singh
MNManmath K. Nandi
Manmath K. Nandi
GMGaurav Mishra
Gaurav Mishra
AMAnand Maurya
Anand Maurya
GKGiriraj T Kulkarni
Giriraj T Kulkarni
Berberine (a protoberberine isoquinoline alkaloid) has shown promising pharmacological activities, including analgesic, anti-inflammatory, anticancer, antidiabetic, anti-hyperlipidemic, cardioprotective, memory enhancement, antidepressant, antioxidant, anti-nociceptive, antimicrobial, anti- HIV and cholesterol-lowering effects. It is used in the treatment of the neurodegenerative disorder. It has strong evidence to serve as a potent phytoconstituent in the treatment of various neurodegenerative disorders such as AD. It limits the extracellular amyloid plaques and intracellular neurofibrillary tangles. It has also lipid-glucose lowering ability, hence can be used as a protective agent in atherosclerosis and AD. However, more detailed investigations along with safety assessment of berberine are warranted to clarify its role in limiting various risk factors and AD-related pathologies. This review highlights the pharmacological basis to control oxidative stress, neuroinflammation and protective effect of berberine in AD, which will benefit to the biological scientists in understanding and exploring the new vistas of berberine in combating Alzheimer’s disease.